Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 3Colorectal Neoplasms, Hereditary Nonpolyposis 2Colorectal Neoplasms 2Barrett Esophagus 2Adenocarcinoma Of Esophagus 2Urogenital Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Lung Neoplasms 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Colitis 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Oxaliplatin 16Cetuximab 13Leucovorin 12Fluorouracil 12Bevacizumab 10pembrolizumab 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 6Irinotecan 6Capecitabine 6encorafenib 4Pemetrexed 4Gemcitabine 4Cisplatin 4cemiplimab 3Folfox protocol 3Early Intervention, Educational 3Carboplatin 3Biopsy 3trifluridine tipiracil drug combination 2relatlimab 2pertuzumab 2palbociclib 2fludarabine 2durvalumab 2dehydroftorafur 2aldesleukin 2adagrasib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Endoscopy × 90 days × Clear all
NCT07405476 2026-04-17

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Emory University

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡